Clinical Trial Update: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Olaparib monotherapy to physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation | Phase 3 | Status: COMPLETED | Results posted: 2017-12-22